المؤلفون: Falk Heidenreich, Elke Rücker-Braun, Juliane S. Walz, Anne Eugster, Denise Kühn, Sevina Dietz, Annika Nelde, Antje Tunger, Rebekka Wehner, Cornelia S. Link, Jan M. Middeke, Friedrich Stölzel, Torsten Tonn, Stefan Stevanovic, Hans-Georg Rammensee, Ezio Bonifacio, Michael Bachmann, Matthias Zeis, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Marc Schmitz

المصدر: Haematologica, Vol 102, Iss 11 (2017)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/8268Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/176e4e3303e44d22aec608b09d162794Test

المؤلفون: Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Peter Brossart, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt

المصدر: Haematologica, Vol 101, Iss 12 (2016)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/7923Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/373bd70facef4c0c81e9f948a298e117Test

المؤلفون: Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Ingo G.H. Schmidt-Wolf, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt

المصدر: Haematologica, Vol 100, Iss 7 (2015)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

الوصف: We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone induction therapy in newly diagnosed multiple myeloma. Based on data from relapsed myeloma, the route of administration for bortezomib was changed from intravenous to subcutaneous after 314 of 604 patients had been enrolled. We analyzed 598 patients who received at least one dose of trial medication. Adverse events were reported more frequently in patients treated with intravenous bortezomib (intravenous=65%; subcutaneous=56%, P=0.02). Rates of grade 2 or more peripheral neuropathy were higher in patients treated with intravenous bortezomib during the third cycle (intravenous=8%; subcutaneous=2%, P=0.001). Overall response rates were similar in patients treated intravenously or subcutaneously. The presence of International Staging System stage III disease, renal impairment or adverse cytogenetic abnormalities did not have a negative impact on overall response rates in either group. To our knowledge this is the largest study to present data comparing subcutaneous with intravenous bortezomib in newly diagnosed myeloma. We show better tolerance and similar overall response rates for subcutaneous compared to intravenous bortezomib. The clinical trial is registered at eudract.ema.europa.eu as n. 2010-019173-16.

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/7442Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/7fc4d92e3bbe4aef88595a9e2be8e126Test

المؤلفون: Stephan Stilgenbauer, Sebastian Böttcher, Hartmut Döhner, Ute Hegenbart, Norbert Schmitz, Lutz Uharek, Michael Stadler, Peter Dreger, Isabelle Krämer, Anthony D. Ho, Sascha Dietrich, Christof Scheid, Matthias Zeis, Michael Hallek, Jörg Thomas Bittenbring, Michael Kneba

المصدر: Blood. 130:1477-1480

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Chronic lymphocytic leukemia, Immunology, Salvage therapy, Biochemistry, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Neoplasm, Hematopoietic cell, business.industry, Cell Biology, Hematology, medicine.disease, Transplantation, Leukemia, chemistry, 030220 oncology & carcinogenesis, Ibrutinib, Alemtuzumab, business, 030215 immunology, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8fbadad1b8b01f25b15055a6900d847aTest
https://doi.org/10.1182/blood-2017-04-775841Test

المؤلفون: Elke Rücker-Braun, Denise Kühn, Antje Tunger, Sevina Dietz, Michael Bachmann, Matthias Zeis, Johannes Schetelig, Cornelia S. Link, Friedrich Stölzel, Gerhard Ehninger, Marc Schmitz, Ezio Bonifacio, Juliane S. Walz, Hans-Georg Rammensee, Falk Heidenreich, Stefan Stevanovic, Rebekka Wehner, Annika Nelde, Torsten Tonn, Jan Moritz Middeke, Anne Eugster, Martin Bornhäuser

المصدر: Haematologica-The Hematology Journal 102(2017), e460-e464

مصطلحات موضوعية: 0301 basic medicine, Adoptive cell transfer, Chronic lymphocytic leukemia, medicine.medical_treatment, Epitopes, T-Lymphocyte, Receptor tyrosine kinase-like orphan receptor, Biology, Receptor Tyrosine Kinase-like Orphan Receptors, Online Only Article, Immunotherapy, Adoptive, Mass Spectrometry, Epitope, 03 medical and health sciences, immune system diseases, hemic and lymphatic diseases, medicine, Humans, Cytotoxic T cell, Antigen Presentation, Hematology, Immunotherapy, medicine.disease, 030104 developmental biology, Immunology, Peptides, Epitope Mapping, Cell signaling pathways, CD8, T-Lymphocytes, Cytotoxic

الوصف: Despite recent treatment improvements with the approval of cell signaling pathway inhibitors, additional treatment options are needed for patients with relapsed/refractory high-risk chronic lymphocytic leukemia (CLL). An emerging immunotherapeutic strategy for CLL is based on the adoptive transfer

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f79157d7be645202ea5993729e2765a0Test
https://doi.org/10.3324/haematol.2017.167312Test

المؤلفون: Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, Hartmut Goldschmidt, Vladimir Maisnar, Philippe Moreau, Chang Ki Min, Agnieszka Pluta, Wee-Joo Chng, Martin Kaiser, Sonja Zweegman, Maria-Victoria Mateos, Andrew Spencer, Shinsuke Iida, Gareth Morgan, Kaveri Suryanarayan, Zhaoyang Teng, Tomas Skacel, Antonio Palumbo, Ajeeta B Dash, Neeraj Gupta, Richard Labotka, S Vincent Rajkumar, Daniel Bar, Alfredo Basso, Dorotea Fantl, Simon He, Neomi Horvath, Cindy Lee, Phillip Rowlings, Kerry Taylor, Tara Cochrane, Fiona Kwok, Sundreswran Ramanathan, Hermine Agis, Niklas Zojer, Alain Kentos, Fritz Offner, Jan Van Droogenbroeck, Ka Lung Wu, Angelo Maiolino, Gracia Martinez, Karla Zanella, Marcelo Capra, Sérgio Araújo, Evzen Gregora, Ludek Pour, Vlastimil Scudla, Ivan Spicka, Niels Abildgaard, Niels Andersen, Bo Amdi Jensen, Carsten Helleberg, Torben Plesner, Morten Salomo, Asta Svirskaite, Richard Delarue, Igor Blau, Aneta Schieferdecker, Veronica Teleanu, Markus Munder, Christoph Röllig, Han-Juergen Salwender, Stephan Fuhrmann, Katja Weisel, Jan Duerig, Matthias Zeis, Stefan Klein, Peter Reimer, Christian Schmidt, Christof Scheid, Karin Mayer, Martin Hoffmann, Markus Sosada, Athanasios Dimopoulos, Sosana Delimpasi, Mary-Christine Kyrtsonis, Achilleas Anagnostopoulos, Zsolt Nagy, Árpád Illés, Miklós Egyed, Zita Borbényi, Gabor Mikala, Najib Dally, Netanel Horowitz, Odit Gutwein, Anatoly Nemets, Iuliana Vaxman, Olga Shvetz, Svetlana Trestman, Rosa Ruchlemer, Arnon Nagler, Tamar Tadmor, Ory Rouvio, Meir Preis, Michele Cavo, Luca De Rosa, Pellegrino Musto, Anna Cafro, Patrizia Tosi, Massimo Offidani, Alessandro Corso, Giuseppe Rossi, Anna Marina Liberati, Alberto Bosi, Kenshi Suzuki, Chiaki Nakaseko, Takayuki Ishikawa, Morio Matsumoto, Hirokazu Nagai, Kazutaka Sunami, Takaaki Chou, Koichi Akashi, Naoki Takezako, Shotaro Hagiwara, Hyeon Seok Eom, Deog-Yeon Jo, Jin Seok Kim, Jae Hoon Lee, Sung Soo Yoon, Dok Hyun Yoon, Kihyun Kim, Mark-David Levin, Edo Vellenga, Monique Minnema, Anders Waage, Einar Haukås, Sebastian Grosicki, Andrzej Pluta, Tadeusz Robak, Herlander Marques, Rui Bergantim, Fernando Campilho, Wee Joo Chng, Yeow Tee Goh, Andrew McDonald, Bernado Rapoport, Miguel Angel Álvarez Rivas, Felipe De Arriba de La Fuente, Yolanda González Montes, Jesus Martin Sanchez, Maria Victoria Mateos, Albert Oriol Rocafiguera, Laura Rosinol, Jesús San Miguel, Jaime Pérez de Oteyza, Cristina Encinas, Adrian Alegre-Amor, Ana López-Guía, Per Axelsson, Kristina Carlson, Olga Stromberg, Markus Hansson, Cecile Hveding Blimark, Rouven Mueller, Chih-Cheng Chen, Ta-Chih Liu, Shang-Yi Huang, Po-Nan Wang, Thanyaphong Na Nakorn, Kannadit Prayongratana, Ali Unal, Hakan Goker, Mehmet Sonmez, Sybiryna Korenkova, Aristeidis Chaidos, Heather Oakervee, Hamdi Sati, Reuben Benjamin, Ashutosh Wechalekar, Mamta Garg, Karthik Ramasamy, Gordon Cook, Andrew Chantry, Matthew Jenner, Francis Buadi, Robert Berryman, Murali Janakiram

المساهمون: Takeda Pharmaceutical Company, Dimopoulos MA1, Gay F2, Schjesvold F3, Beksac M4, Hajek R5, Weisel KC6, Goldschmidt H7, Maisnar V8, Moreau P9, Min CK10, Pluta A11, Chng WJ12, Kaiser M13, Zweegman S14, Mateos MV15, Spencer A16, Iida S17, Morgan G18, Suryanarayan K19, Teng Z19, Skacel T19, Palumbo A20, Dash AB19, Gupta N19, Labotka R19, Rajkumar SV21, TOURMALINE-MM3 study group. Bar D, Basso A, Fantl D, He S, Horvath N, Lee C, Rowlings P, Taylor K, Spencer A, Cochrane T, Kwok F, Ramanathan S, Agis H, Zojer N, Kentos A, Offner F, Van Droogenbroeck J, Wu KL, Maiolino A, Martinez G, Zanella K, Capra M, Araújo S, Gregora E, Hajek R, Maisnar V, Pour L, Scudla V, Spicka I, Abildgaard N, Andersen N, Jensen BA, Helleberg C, Plesner T, Salomo M, Svirskaite A, Delarue R, Moreau P, Blau I, Goldschmidt H, Schieferdecker A, Teleanu V, Munder M, Röllig C, Salwender HJ, Fuhrmann S, Weisel K, Duerig J, Zeis M, Klein S, Reimer P, Schmidt C, Scheid C, Mayer K, Hoffmann M, Sosada M, Dimopoulos A, Delimpasi S, Kyrtsonis MC, Anagnostopoulos A, Nagy Z, Illés Á, Egyed M, Borbényi Z, Mikala G, Dally N, Horowitz N, Gutwein O, Nemets A, Vaxman I, Shvetz O, Trestman S, Ruchlemer R, Nagler A, Tadmor T, Rouvio O, Preis M, Gay F, Cavo M, De Rosa L, Musto P, Cafro A, Tosi P, Offidani M, Corso A, Rossi G, Liberati AM, Bosi A, Suzuki K, Iida S, Nakaseko C, Ishikawa T, Matsumoto M, Nagai H, Sunami K, Chou T, Akashi K, Takezako N, Hagiwara S, Eom HS, Jo DY, Kim JS, Lee JH, Min CK, Yoon SS, Yoon DH, Kim K, Zweegman S, Levin MD, Vellenga E, Minnema M, Schjesvold F, Waage A, Haukås E, Grosicki S, Pluta A, Robak T, Marques H, Bergantim R, Campilho F, Chng WJ, Goh YT, McDonald A, Rapoport B, Álvarez Rivas MA, De Arriba de La Fuente F, González Montes Y, Martin Sanchez J, Mateos MV, Oriol Rocafiguera A, Rosinol L, San Miguel J, Pérez de Oteyza J, Encinas C, Alegre-Amor A, López-Guía A, Axelsson P, Carlson K, Stromberg O, Hansson M, Hveding Blimark C, Mueller R, Chen CC, Liu TC, Huang SY, Wang PN, Na Nakorn T, Prayongratana K, Beksac M, Unal A, Goker H, Sonmez M, Korenkova S, Chaidos A, Oakervee H, Sati H, Benjamin R, Wechalekar A, Garg M, Kaiser M, Ramasamy K, Cook G, Chantry A, Jenner M, Buadi F, Berryman R, Janakiram M., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, CCA - Cancer biology and immunology, Hematology

المصدر: Dimopoulos, M A, Gay, F, Schjesvold, F, Beksac, M, Hajek, R, Weisel, K C, Goldschmidt, H, Maisnar, V, Moreau, P, Min, C K, Pluta, A, Chng, W-J, Kaiser, M, Zweegman, S, Mateos, M-V, Spencer, A, Iida, S, Morgan, G, Suryanarayan, K, Teng, Z, Skacel, T, Palumbo, A, Dash, A B, Gupta, N, Labotka, R, Rajkumar, S V, Abildgaard, N & TOURMALINE-MM3 study group 2019, ' Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 253-264 . https://doi.org/10.1016/S0140-6736Test(18)33003-4
Dimopoulos, M A, Gay, F, Schjesvold, F, Beksac, M, Hajek, R, Weisel, K C, Goldschmidt, H, Maisnar, V, Moreau, P, Min, C K, Pluta, A, Chng, W J, Kaiser, M, Zweegman, S, Mateos, M V, Spencer, A, Iida, S, Morgan, G, Suryanarayan, K, Teng, Z, Skacel, T, Palumbo, A, Dash, A B, Gupta, N, Labotka, R, Rajkumar, S V, Kwok, F & TOURMALINE-MM3 study group 2019, ' Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial ', The Lancet, vol. 393, no. 10168, pp. 253-264 . https://doi.org/10.1016/S0140-6736Test(18)33003-4
Digital.CSIC. Repositorio Institucional del CSIC
instname
Lancet, 393(10168), 253. Elsevier Limited
LANCET, 393(10168), 253-264. ELSEVIER SCIENCE INC
The Lancet, 393(10168), 253-264. Elsevier Limited

مصطلحات موضوعية: Male, Time Factors, DIAGNOSED MULTIPLE-MYELOMA, Clinical Trial, Phase III, Administration, Oral, 030204 cardiovascular system & hematology, Ixazomib, chemistry.chemical_compound, 0302 clinical medicine, Autologous stem-cell transplantation, Maintenance therapy, Clinical endpoint, 030212 general & internal medicine, Non-U.S. Gov't, Boron Compounds/administration & dosage, IMPROVES SURVIVAL, INDUCTION, Research Support, Non-U.S. Gov't, General Medicine, CHEMOTHERAPY, Middle Aged, Clinical Trial, DEXAMETHASONE, Antineoplastic Agents/administration & dosage, Multicenter Study, Treatment Outcome, Administration, Randomized Controlled Trial, Disease Progression, Female, Multiple Myeloma, Autologous, Boron Compounds, Oral, medicine.medical_specialty, Glycine, Multiple Myeloma/drug therapy, BORTEZOMIB, Antineoplastic Agents, Placebo, Research Support, Transplantation, Autologous, 03 medical and health sciences, Phase III, Double-Blind Method, Internal medicine, medicine, Journal Article, Humans, THALIDOMIDE, Transplantation, business.industry, Clinical trial, LENALIDOMIDE MAINTENANCE, Regimen, chemistry, autologous stem cell transplantation, multiple myeloma, Ixazomib, business, HIGH-DOSE THERAPY, Glycine/administration & dosage, Stem Cell Transplantation

الوصف: [Background]: Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT. [Methods]: The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place in 167 clinical or hospital sites in 30 countries in Europe, the Middle East, Africa, Asia, and North and South America. Eligible participants were adults with a confirmed diagnosis of symptomatic multiple myeloma according to International Myeloma Working Group criteria who had achieved at least a partial response after undergoing standard-of-care induction therapy followed by high-dose melphalan (200 mg/m²) conditioning and single ASCT within 12 months of diagnosis. Patients were randomly assigned in a 3:2 ratio to oral ixazomib or matching placebo on days 1, 8, and 15 in 28-day cycles for 2 years following induction, high-dose therapy, and transplantation. The initial 3 mg dose was increased to 4 mg from cycle 5 if tolerated during cycles 1–4. Randomisation was stratified by induction regimen, pre-induction disease stage, and response post-transplantation. The primary endpoint was progression-free survival (PFS) by intention-to-treat analysis. Safety was assessed in all patients who received at least one dose of ixazomib or placebo, according to treatment actually received. This trial is registered with ClinicalTrials.gov, number NCT02181413, and follow-up is ongoing. [Findings]: Between July 31, 2014, and March 14, 2016, 656 patients were enrolled and randomly assigned to receive ixazomib maintenance therapy (n=395) or placebo (n=261). With a median follow-up of 31 months (IQR 27·3–35·7), we observed a 28% reduction in the risk of progression or death with ixazomib versus placebo (median PFS 26·5 months [95% CI 23·7–33·8] vs 21·3 months [18·0–24·7]; hazard ratio 0·72, 95% CI 0·58–0·89; p=0·0023). No increase in second malignancies was noted with ixazomib therapy (12 [3%] patients) compared with placebo (eight [3%] patients) at the time of this analysis. 108 (27%) of 394 patients in the ixazomib group and 51 (20%) of 259 patients in the placebo group experienced serious adverse events. During the treatment period, one patient died in the ixazomib group and none died in the placebo group. [Interpretation]: Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma
This study was sponsored by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company.

وصف الملف: image/pdf; application/pdf; STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de353f2eca3bce4266841424f74a30cTest
http://hdl.handle.net/2318/1732833Test

المؤلفون: Markus Munder, Matthias Zeis, Hartmut Goldschmidt, Anna Jauch, Thomas Hielscher, Elias K. Mai, Mathias Haenel, Christof Scheid, Peter Brossart, Anja Seckinger, Dirk Hose, Maximilian Merz, Jens Hillengass, Christian Gerecke, Hans Walter Lindemann, Baerbel Schurich, Igor Wolfgang Blau, Marc-Steffen Raab, Uta Bertsch, Christina Kunz, Jan Duerig, Hans Salwender, Katja Weisel

المساهمون: Hematology, Basic (bio-) Medical Sciences

المصدر: Haematologica. 101:e485-e487

مصطلحات موضوعية: medicine.medical_specialty, Peripheral Nervous System Diseases/chemically induced, Multiple Myeloma/complications, Medizin, Newly diagnosed, Neurotoxic agents, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, Humans, risk factors, Genetics(clinical), In patient, Online Only Articles, Multiple myeloma, Bortezomib, business.industry, Antineoplastic Agents/adverse effects, Hematology, medicine.disease, Surgery, Thalidomide, Clinical trial, Peripheral neuropathy, 030220 oncology & carcinogenesis, Bortezomib/administration & dosage, Induction Chemotherapy/adverse effects, business, 030215 immunology, medicine.drug

الوصف: Up to 20% of patients with multiple myeloma (MM) show signs of peripheral neuropathy (PN) at primary diagnosis.[1][1] Treatment with neurotoxic agents such as bortezomib or thalidomide increases rates of PN in newly diagnosed patients by up to 50%.[2][2] Since subcutaneous (SC) administration

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1faee40fdb1121975794e8ec8514b75Test
https://doi.org/10.3324/haematol.2016.151266Test

المؤلفون: Malte Plidschun, Matthias Zeisberger, Jisoo Kim, Torsten Wieduwilt, Markus A. Schmidt

المصدر: Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract The generation of tailored light fields with spatially controlled intensity and phase distribution is essential in many areas of science and application, while creating such patterns remotely has recently defined a key challenge. Here, we present a fiber-compatible concept for the remote generation of complex multi-foci three-dimensional intensity patterns with adjusted relative phases between individual foci. By extending the well-known Huygens principle, we demonstrate, in simulations and experiments, that our interference-based approach enables controlling of both intensity and phase of individual focal points in an array of spots distributed in all three spatial directions. Holograms were implemented using 3D nano-printing on planar substrates and optical fibers, showing excellent agreement between design and implemented structures. In addition to planar substrates, holograms were also generated on modified single-mode fibers, creating intensity distributions consisting of about 200 individual foci distributed over multiple image planes. The presented scheme yields an innovative pathway for phase-controlled 3D digital holography over remote distances, yielding an enormous potential application in fields such as quantum technology, life sciences, bioanalytics and telecommunications. Overall, all fields requiring precise excitation of higher-order optical resonances, including nanophotonics, fiber optics and waveguide technology, will benefit from the concept.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/ac02555c0aaa4f4da348066880dc41edTest

المؤلفون: Justin Hasenkamp, Anke Görlitz, Gerald Wulf, Sebastian Pfeiffer, Lorenz Truemper, Gerda Silling, Michael Pfreundschuh, Martin Gramatzki, Bertram Glass, Norbert Schmitz, Christian Wilhelm, Matthias Zeis, Peter Dreger, Reinhard Hilgers

المصدر: The Lancet Oncology. 15:757-766

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Transplantation Conditioning, medicine.medical_treatment, Population, Graft vs Host Disease, Aggressive Non-Hodgkin Lymphoma, Hematopoietic stem cell transplantation, Antibodies, Monoclonal, Murine-Derived, Recurrence, Internal medicine, Humans, Transplantation, Homologous, Medicine, Cumulative incidence, education, education.field_of_study, business.industry, Lymphoma, Non-Hodgkin, Hematopoietic Stem Cell Transplantation, Middle Aged, Combined Modality Therapy, Surgery, Transplantation, Oncology, Female, Rituximab, business, Busulfan, medicine.drug

الوصف: Allogeneic stem-cell transplantation has had limited success for patients with refractory and relapsed aggressive B-cell or T-cell lymphoma. We investigated the effect of adding rituximab to standard prophylaxis for graft-versus-host disease after transplantation and estimated overall survival when using a lymphoma-directed myeloablative conditioning regimen.We did this randomised, open-label, phase 2 study at seven German transplantation centres. We enrolled patients with aggressive B-cell or T-cell lymphoma and primary refractory disease, early relapse (12 months after first-line treatment), or relapse after autologous transplantation. Conditioning with fludarabine (125 mg/m(2)), busulfan (12 mg/kg oral or 9·6 mg/kg intravenous), and cyclophosphamide (120 mg/kg) was followed by allogeneic stem-cell transplantation. Patients were randomly assigned (1:1) to receive rituximab (375 mg/m(2) on days 21, 28, 35, 42, 175, 182, 189, and 196) or not. Allocation was done with a centralised computer-generated procedure; patients were stratified by histological subtype (B-cell vs T-cell lymphoma) and donor match (HLA-identical vs non-identical). Neither investigators nor patients were masked to allocation. The primary endpoints were the incidence of acute graft-versus-host disease grade 2-4 in each treatment group and overall survival at 1 year in both groups combined. All analyses were done for the intention-to-treat population. The study is registered with ClinicalTrials.gov, number NCT00785330.Between June 16, 2004, and March 24, 2009, we screened 86 patients and enrolled 84; 42 were randomly assigned to each group. The cumulative incidence of grade 2-4 acute graft-versus-host disease was 46% (95% CI 32-62) in the rituximab group and 42% (95% CI 29-59) in the no rituximab group (hazard ratio [HR] 0·91, 95% CI 0·52-1·60; p=0·74). Overall survival at 1 year for the whole study population was 52% (95% CI 41-62). Grade 4 haematological toxic effects and grade 3 alopecia occurred in all patients. The most common non-haematological grade 5 toxic effects were pneumonia (nine in the no rituximab group vs ten in the rituximab group) and other infections (seven vs four).The lymphoma-directed myeloablative conditioning regimen developed here is promising for patients with refractory and relapsed aggressive B-cell and T-cell lymphomas. However, the addition of rituximab did not affect the incidence of graft-versus-host disease or overall survival.Hoffmann-La Roche, Amgen, Astellas Pharma.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8abf65489dfe210e357f25a5763e12f2Test
https://doi.org/10.1016/s1470-2045Test(14)70161-5

المؤلفون: Donald Bunjes, Sonia Jaramillo, Christoph Scheid, Matthias Ritgen, Eugen Tausch, Hartmut Döhner, Daniela Steinbrecher, Matthias Zeis, Sebastian Böttcher, Annika Scheffold, Peter Dreger, Michael Hallek, Lutz Uharek, Norbert Schmitz, Stephan Stilgenbauer, Michael Hahn, Michael Stadler, Ute Hegenbart, Billy Michael Chelliah Jebaraj, Michael Kneba

المصدر: British journal of haematology. 179(2)

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Immunoglobulin Variable Region, Disease, 03 medical and health sciences, 0302 clinical medicine, Clinical Trials, Phase II as Topic, Internal medicine, medicine, Humans, Multicenter Studies as Topic, Transplantation, Homologous, In Situ Hybridization, Fluorescence, Telomere Shortening, Chromosome Aberrations, Lymphocytic leukaemia, Poor risk, business.industry, Hematopoietic Stem Cell Transplantation, Telomere Homeostasis, Hematology, Telomere, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Transplantation, Treatment Outcome, 030220 oncology & carcinogenesis, Mutation, Stem cell, business, Immunoglobulin Heavy Chains, 030215 immunology, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2104ed4106cc974554ca86b2dbd4268Test
https://pubmed.ncbi.nlm.nih.gov/27391907Test